Our Technology Advantage

GreenStar is focused on obtaining best in class technology to advance its operations and brands to stay at the forefront of technology innovation and transformational medicine.

Eleusian Biosciences brings multiple provisional patents

Patents:

  1. U.S. Provisional Patent Application entitled “Device and Method for the Treatment of Traumatic Brain Injuries and Post-Traumatic Stress Disorder” Serial No.: 63/016,455 Filing Date: April 28, 2020
  2. U.S. Provisional Patent Application entitled “Methods and Compositions for Treating Post Traumatic Stress Disorder or Mild Traumatic Brain Injury with Post Traumatic Stress Disorder” Serial No.: 63/012,435 Filing Date: April 20, 2020
  3. The third provisional patent application, Serial No.: 63/040,032, is for methods and compositions for treating mild traumatic brain injury/concussion (“mTBI”) with post-traumatic stress disorder (“PTSD”) or PTSD alone with 3,4-methylenedioxymethamphetamine (“MDMA”) plus N-acetylcysteine (“NAC”).
    Effectively, Eleusian has filed provisional patent protection for two different psychedelic compounds combined with NAC for the treatment of mTBI and PTSD and a unique medicine delivery system that can deliver precise dosing through the nasal lobes.

     

Our Plan

Stage 1: Pre-Clinical Studies

Eleusian’s development program begins with basic science investigations to demonstrate safety and efficacy of the combination of Psilocybin and NAC in treating mild traumatic brain injury (mTBI) with PTSD or PTSD alone in established rodent models.

Stage 2: IND-enabling Pre-clinical Studies

Following successful demonstration of safety and efficacy of the combination of Psilocybin and NAC in the treatment of mTBI with PTSD or PTSD alone, Eleusian plans to conduct pre-clinical studies (including GLP toxicology, ADME, as well as formulation and manufacturing development) necessary to file an Investigational New Drug (IND) application.

Stage 3: Human Clinical Trials

Following regulatory approval of our IND, Eleusian plans to initiate human clinical trials of the combination of Psilocybin and NAC in the treatment of mTBI with PTSD or PTSD alone in collaboration with investigators at the University of Miami and other leading clinical research institutions.

cannabis thin strips icon

Heading into university sponsored clinical studies

Related studies showing promise and progress

Arrow Striking Target

Exceptional and qualified team